多模态医疗大模型加速落地，创新药支付模式拓展新空间

Industry Insights - The Zhejiang Provincial Health Commission and other departments have launched an action plan to accelerate the high-quality development of "Artificial Intelligence + Healthcare," focusing on creating multimodal medical industry models and autonomous AI research frameworks [1] - The plan aims to develop specialized models and medical intelligent systems covering various areas such as medical services, health management, public health, and drug/device research [1] - Significant technology projects will be implemented in fields like AI data and applications, brain-computer interfaces, and new drug development, with an emphasis on interdisciplinary collaboration in medical AI research [1] Market Trends - The report from Founder Securities highlights that the "Artificial Intelligence +" initiative is driving revolutionary changes in the medical industry, with rapid deployment of high-end innovative devices like brain-computer interfaces and surgical robots [2] - The commercialization of non-invasive brain-computer interfaces is accelerating, particularly in medical rehabilitation and emotional management, indicating a broad market potential [2] - The AI healthcare sector is expected to see accelerated commercialization due to supportive policies, with AI applications in pathology diagnosis, imaging, and drug development being relatively mature [2] Company Developments - Sanbo Brain Science focuses on high-barrier technologies in neurosurgery, leveraging a "medical education research" system for technology transfer and expansion, positioning itself well in the private brain healthcare sector amid aging and precision medicine trends [3] - WuXi AppTec is centered on empowering the entire chain of innovative drugs with AI, benefiting from high technical barriers and global production capabilities, particularly in the context of GLP-1 and gene therapy trends [4]